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Abstract
Background Clinical phenotypic heterogeneity represents a major barrier to trials in motor neuron disease (MND) and 
objective surrogate outcome measures are required, especially for slowly progressive patients. We assessed responsiveness 
of clinical, electrophysiological and radiological muscle-based assessments to detect MND-related progression.
Materials and methods A prospective, longitudinal cohort study of 29 MND patients and 22 healthy controls was performed. 
Clinical measures, electrophysiological motor unit number index/size (MUNIX/MUSIX) and relative T2- and difusion-
weighted whole-body muscle magnetic resonance (MR) were assessed three times over 12 months. Multi-variable regression 
models assessed between-group diferences, clinico-electrophysiological associations, and longitudinal changes. Standardized 
response means (SRMs) assessed sensitivity to change over 12 months.
Results MND patients exhibited 18% higher whole-body mean muscle relative T2-signal than controls (95% CI 7–29%, 
p < 0.01), maximal in leg muscles (left tibialis anterior 71% (95% CI 33–122%, p < 0.01). Clinical and electrophysiological 
associations were evident. By 12 months, 16 patients had died or could not continue. In the remainder, relative T2-signal 
increased over 12 months by 14–29% in right tibialis anterior, right quadriceps, bilateral hamstrings and gastrocnemius/soleus 
(p < 0.01), independent of onset-site, and paralleled progressive weakness and electrophysiological loss of motor units. High-
est clinical, electrophysiological and radiological SRMs were found for revised ALS-functional rating scale scores (1.22), 
tibialis anterior MUNIX (1.59), and relative T2-weighted leg muscle MR (right hamstrings: 0.98), respectively. Difusion 
MR detected minimal changes.
Conclusion MUNIX and relative T2-weighted MR represent objective surrogate markers of progressive denervation in 
MND. Radiological changes were maximal in leg muscles, irrespective of clinical onset-site.
Keywords Muscle · MRI · Motor neuron disease · Amyotrophic lateral sclerosis · MUNIX
Introduction
A signiicant challenge in motor neuron disease/amyotrophic 
lateral sclerosis (MND/ALS) research is the facility to track 
disease changes objectively over manageable time-scales, to 
reduce the duration and expense of clinical trials. Whilst sur-
vival remains a commonly applied outcome measure, slower 
progressing patients appear relatively over-represented in 
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clinical trials [1, 2], and surrogate outcome measures are 
necessary to detect therapeutic efects in this group. The 
revised ALS functional rating scale (ALSFRS-R) question-
naire [3] is frequently used, but has well recognized limita-
tions, including inherent subjectivity and inluence of symp-
tomatic treatment [4, 5]. Objective biomarkers are, therefore, 
required; imaging and electrophysiology appear promising 
candidates [6, 7].
Clinical heterogeneity in anatomical site of onset, pattern 
of spread, and rate of deterioration are important barriers 
to quantifying progression at group-level, whether using 
clinical, electrophysiological or radiological measures. 
Most previous imaging studies have focused on the central 
nervous system (116 in a recent review [8]), and there are 
relatively few studies of MND efects on peripheral nerve 
[9–11] or muscle [9, 10, 12–17], yet denervation and mus-
cle weakness are cardinal clinico-pathological features. 
Approximately 25% of MND patients present with bulbar 
weakness and 70% with either upper or lower limb muscular 
weakness in similar proportions [18]. It is, therefore, chal-
lenging to capture the disparate efects of denervation on an 
individual’s muscles objectively and translate into a group-
level parameter suitable for a trial. This may be addressed 
by application of clinical scores or electrophysiology to 
multiple muscles, or by whole-body muscle magnetic reso-
nance (MR) imaging. In previous work, we reported longi-
tudinal relative T2-weighted changes, derived from whole-
body MR, in tibialis anterior over 4 months [17]. In this 
study, we present a new and comprehensive analysis of a 
wide range of clinical, electrophysiological and radiological 
muscle measures, including both T2- and difusion-weighted 
MR, tested in multiple muscles over an extended follow-up 
period of 12 months. The aim was to identify individual-
ized muscle denervation patterns in MND, and the objective 
was to assess the optimal technique to detect group-level 
change from a variety of clinical, electrophysiological and 
radiological candidates. We hypothesized that whole-body 
T2- and difusion-weighted muscle MR would enable quan-
tiication of generalized denervation, regardless of clinical 
site of onset.
Methods
Study population
This was a prospective, longitudinal, observational cohort 
study. Patients were identiied at irst presentation to the 
tertiary referral neuromuscular clinic at the Royal Hallam-
shire Hospital, Sheield, UK and were assessed at baseline, 
4 and 12 months between October 2013 and May 2016. 
Inclusion criteria were age > 18 years, a clinical diagnosis 
of ALS fulilling El Escorial criteria [19] or progressive 
muscular atrophy. Participation in interventional studies 
was recorded. Exclusion criteria were cognitive impairment 
suicient to impair consent, contraindications to MR imag-
ing, pregnancy, another neuromuscular disease, or respira-
tory failure impairing the ability to lie lat in the scanner. 
Healthy controls were recruited from partners of patients 
and by advertisement, and assessed at two time-points. 
Based on the results of our previous study [17], the primary 
outcome selected was between-group diferences in relative 
T2-weighted MR signal over time and, in order to satisfy 
the requirement of at least 10–20 observations per degree 
of freedom for the linear regression models (with age and 
gender as covariates), a minimum sample size of 30–60 
observations was required [20]. Secondary outcomes were 
between-group diferences in clinical, electrophysiological 
and difusion-weighted MR measures, inter-modality asso-
ciations and change over time.
Clinical assessments
Demographic data, site of onset and duration of weakness 
were recorded. At each visit, the following data were col-
lected: weight; revised ALSFRS-R [3]; Medical Research 
Council scores [21] from bilateral deltoids, biceps brachii, 
triceps, wrist lexors, wrist extensors, inger lexors, inger 
extensors, abductor pollicis brevis, irst dorsal interosseous, 
abductor digiti minimi, hip lexors, hip extensors, ham-
strings, quadriceps, ankle dorsilexors, ankle plantar lexors, 
and neck lexors and neck extensors, resulting in an MRC 
summary score (maximum 170); hand-held dynamometry 
scores in bilateral irst dorsal interosseous, abductor pol-
licis brevis, abductor digiti minimi, quadriceps and ankle 
dorsilexors.
Electrophysiology
Compound muscle action potentials (CMAPs), motor unit 
number index (MUNIX) and motor unit size (MUSIX) [22] 
were obtained from the least clinically afected side, to avoid 
“floor” effects using surface electromyography (Dantec 
Keypoint, Natus Medical, California) following standard-
ized protocols [23] in the following muscles: biceps bra-
chii, abductor pollicis brevis, abductor digit minimi, tibialis 
anterior, abductor hallucis, and extensor digitorum brevis. 
In healthy controls, the right side was tested.
Radiology
T2-weighted fast spin-echo and difusion-weighted imag-
ing (DWI) sequences were obtained at 3  T (Philips 
Ingenia, Best, Netherlands) with the following param-
eters: T2: TR = 1107 ms, TE = 80 ms, interpolated voxel 
size 0.78 × 0.78 × 5 mm3, 5–6 stations, 50 coronal slices, 
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reformatted to correspond to axial DWI acquisitions; DWI: 
TR = 9412 ms, TE = 66 ms, TI = 250 ms, b0, b1000 s/mm2, 
voxel size 2.3 × 2.3 × 5 mm3, eight stations, 50 axial slices. 
Total acquisition times including localizers and breath-holds 
were approximately 20 min and 40 min for the T2- and dif-
fusion-weighted acquisitions, respectively.
Muscle regions-of-interest were contoured by two 
observers using standardized anatomical landmarks using a 
semi-automated spline function (Extended MR Workspace 
V2.6.3.5, Philips) on single slices for both T2- and difusion-
weighted images (Fig. 1a–i). Prior to analysis, intra- and 
inter-rater reproducibility was conirmed by coeicients of 
variability of < 5% for all regions-of-interest on six datasets 
reassessed after > 24 h. Mean relative T2 estimates were 
obtained from the following muscles and muscle groups in 
axial orientation: tongue, splenius capitis, bilateral trapezius, 
sternocleidomastoid, deltoid, biceps brachii, forearm com-
partment encompassing brachioradialis, thoracic paraspi-
nal, psoas major, gluteus maximus, quadriceps, hamstrings, 
tibialis anterior, and gastrocnemius/soleus. Triceps, irst 
dorsal interosseous, thenar and hypothenar eminence were 
also assessed but on coronal rather than axial T2 images, 
as anatomical boundaries were more consistently identii-
able. Apparent difusion coeicient (ADC) estimates were 
obtained from each of the muscles assessed in axial orien-
tation and not from intrinsic hand muscles and triceps. To 
adjust for coil-loading efects, relative T2 estimates were 
expressed as a ratio to a bone reference within the same 
acquisition station [17] (Supplemental Material); no adjust-
ment was made for ADC.
Statistical analysis
Stata version 13.1 was used (StataCorp, Texas). For 
between-group comparisons and associations, p values 
were reported corrected for age and gender, due to poten-
tial influences on muscle parameters [24]. All p values 
were corrected for multiple comparisons by applying the 
Fig. 1  Coronal whole-body T2-weighted acquisition (a); axial slices 
from relative T2-weighted (b, d, f, h) and apparent difusion coei-
cient (c, e, g, i) maps from head and neck station depicting right and 
left sternocleidomastoid and splenius capitis (b, c); thoracic station 
depicting right and left thoracic paraspinals (d, e); upper leg station 
depicting right quadriceps and hamstring groups (f, g) and lower 
leg station depicting right tibialis anterior and gastrocnemius/soleus 
groups (h, i). Coronal images from the lower leg station shown to 
illustrate an increase in relative T2-weighted signal in tibialis anterior 
and gastrocnemius/soleus groups in an MND patient between base-
line (j) and 12 months (k). ADC apparent difusion coeicient, gas-
trocs gastrocnemius, SCM sternocleidomastoid, TA tibialis anterior, 
TP thoracic paraspinal
 Journal of Neurology
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Benjamini–Hochberg method to each table of results at each 
time-point, [25] and results where signiicance was retained 
were asterisked.
Baseline diferences between MND patients and controls
For continuous variables, between-group diferences were 
assessed using multiple regression models, entering each 
clinical, electrophysiological and radiological variable 
of interest, in turn, as the dependent variable, and group 
(patient/control), age and gender entered as independent 
variables. Between-group diferences in categorical vari-
ables were assessed using chi-squared tests.
Results were reported as the diference in each parameter 
between patients and controls, derived from the regression 
models, expressed as a percentage ratio, with between-group 
diference the numerator, and control mean the denominator. 
Ratio 95% conidence intervals were calculated [26]. For 
ordinal MRC scores, the proportion of patients with weak-
ness in each muscle (MRC < 5) was reported.
Clinical, electrophysiological and radiological associations
Associations between clinical, electrophysiological and 
radiological variables were assessed using separate multiple 
regression models, entering each clinical or electrophysi-
ological variable, in turn, as the dependent variable, and the 
anatomically corresponding radiological variable, for rela-
tive T2 and ADC in each muscle, in turn, as an independent 
variable. Age and gender were entered into the model as 
additional independent variables.
Longitudinal changes
For continuous variables, longitudinal changes were mod-
elled using mixed efects linear regression, with each clini-
cal, electrophysiological and radiological variable entered, 
in turn, as the dependent variable, and time-point (as a cat-
egorical variable) and subject entered as independent vari-
ables. No assumptions were made on covariance structure. 
All available data were entered. Separate models were run 
for each variable, and for patients and controls. For radio-
logical variables, percentage signal change compared to 
baseline was reported.
In addition to investigating each individual muscle sepa-
rately, two additional analyses were performed to assess per-
formance of radiological muscle estimates individualized 
to clinical onset-site to determine whether it was possible 
to increase sensitivity to detect group-level efects by indi-
vidualizing damage measures to anatomical site of onset. 
First, for each subject, a single muscle was chosen to rep-
resent onset-site: tongue for bulbar-onset, right or left irst 
dorsal interosseous for upper limb-onset and tibialis anterior 
for lower limb-onset (chosen because commonly clinically 
afected) [27]. These signal estimates were speciied as a 
“muscle-of-onset” dependent variable, into a mixed efects 
regression model, entering time-point and subject as inde-
pendent variables.
Second, for each subject, mean signal estimates were 
calculated from all muscles in the region-of-onset (tongue, 
trapezius and sternocleidomastoids for bulbar-onset; right 
or left deltoid, biceps, triceps, forearm compartment, irst 
dorsal interosseous, thenar and hypothenar eminence for 
upper limb-onset; right or left psoas, gluteus maximus, 
quadriceps, hamstrings, tibialis anterior and gastrocnemius 
for lower limb-onset). These estimates were speciied as a 
“region-of-onset” dependent variable, into a mixed efects 
regression model, entering time-point and subject as inde-
pendent variables.
To compare these diferent strategies for detecting lon-
gitudinal relative T2-signal change in individuals, plots 
for each patient were reported for the following measures, 
selected post-hoc: whole-body muscle summary mean, 
region-of-onset, muscle-of-onset and a single leg muscle 
(right tibialis anterior).
The responsiveness of each normally distributed lon-
gitudinal outcome measure was reported using standard-
ized response means (mean change between baseline and 
12 months divided by its standard deviation); values > 0.8 
are considered highly responsive [28].
To quantify within-subject heterogeneity for each meas-
ure, variance ratios were reported, derived from regression 
model outputs, by dividing the variance of the regression 
model constant (the ixed efects, representing group-level 
disease efect) by the summed variance of the constant and 
residual variance (the random efects, representing inter-
individual variability). Lower values indicate greater relative 
within-group phenotypic variability.
Median diferences in ordinal MRC scores were assessed 
using Wilcoxon matching-pairs tests.
Baseline predictors of muscle weakness
To determine whether baseline relative T2-weighted mus-
cle signal predicted development of weakness at four and 
12 months, clinical change variables were generated by cal-
culating MRC score diferences (four and 12 months minus 
baseline, respectively). Each of these change variables was 
entered as the dependent variable in separate regression 
models with baseline relative T2 from the corresponding 
muscle group as the independent variable. This analysis was 
performed only in muscles with corresponding clinical and 
radiological data, namely splenius capitis, deltoid, biceps 
brachii, irst dorsal interossei, psoas major, gluteus maximus, 
quadriceps, hamstrings, tibialis anterior, and gastrocnemius/
soleus. To determine whether relative T2-signal in clinically 
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strong muscles was associated with development of weak-
ness, the analysis was repeated after excluding muscles with 
MRC score < 5/5; sample sizes for each muscle are reported 
in Table 1.
Results
Study population
Twenty-nine MND patients (26 ALS and 3 progressive mus-
cular atrophy) and 22 healthy volunteers entered the study. 
Follow-up rates are reported in Fig. 2. No patients partici-
pated in any interventional research during the course of the 
study. There were no diferences in age, gender and weight 
Table 1  Radiological 
diferences between MND 
patients and controls, and 
proportion of patients with 
clinical weakness, by muscle, 
at baseline, listed in order of 
maximal signiicant radiological 
diferences
Signiicant diferences in radiological parameters between MND patients and controls are highlighted in 
bold. Results surviving multiple comparisons correction are asterisked
CI conidence interval, MRC Medical Research Council
Muscle Mean % diference in relative 
T2-signal patients > controls (95% 
CI)
p value Proportion of patients with 
clinical weakness MRC < 5
(95% CI)
Left tibialis anterior 71.4 (32.7, 122.2) < 0.001* 0.43 (0.26, 0.62)
Left quadriceps 42.1 (14.0, 74.2) 0.004* 0.04 (0.005, 0.23)
Right quadriceps 37.9 (14.4, 63.8) 0.002* 0.04 (0.005, 0.23)
Left gastrocnemius/soleus 37.8 (11.7, 66.7) 0.005* 0.14 (0.05, 0.33)
Right gastrocnemius/soleus 37.6 (15.0, 62.4) 0.002* 0.11 (0.03, 0.30)
Right hamstrings 36.3 (7.4, 68.8) 0.015 0.39 (0.23, 0.59)
Left hamstrings 33.7 (9.3, 60.5) 0.008* 0.36 (0.20, 0.55)
Right hypothenar eminence 31.3 (4.0, 61.7) 0.028 0.61 (0.41, 0.77)
Right tibialis anterior 30.4 (5.5, 57.5) 0.018 0.50 (0.32, 0.68)
Right thoracic paraspinals 26.9 (2.3, 53.5) 0.033 Not tested
Left hypothenar eminence 26.5 (5.1, 49.3) 0.017 0.82 (0.63, 0.93)
Left thoracic paraspinals 26.1 (0.2, 54.0) 0.049 Not tested
Right irst dorsal interosseus 24.7 (1.4, 49.7) 0.040 0.64 (0.45, 0.80)
Right biceps brachii 22.8 (7.5, 38.8) 0.004* 0.21 (0.10, 0.41)
Summary mean 18.0 (6.7, 29.5) 0.001* Not applicable
Right deltoid 15.0 (0.8, 29.5) 0.039 0.39 (0.23, 0.59)
Tongue 11.4 (1.7, 21.2) 0.022 Not tested
Left irst dorsal interosseous 57.8 (− 2.8, 151.1) 0.062 0.68 (0.48, 0.83)
Left thenar eminence 24.1 (− 26.0, 82.0) 0.330 0.50 (0.32, 0.68)
Right thenar eminence 20.5 (− 1.8, 44.0) 0.073 0.50 (0.32, 0.68)
Left gluteus maximus 15.7 (− 34.1, 70.3) 0.517 0.04 (0.005, 0.23)
Left deltoid 12.6 (− 0.1, 25.7) 0.053 0.32 (0.17, 0.52)
Right gluteus maximus 12.1 (− 21.4, 47.3) 0.365 0.04 (0.005, 0.23)
Left biceps brachii 11.6 (− 0.2, 25.4) 0.094 0.11 (0.03, 0.30)
Left trapezius 10.4 (− 4.9, 26.1) 0.374 Not tested
Right triceps 10.1 (− 30.3, 52.3) 0.609 0.14 (0.05, 0.33)
Right sternocleidomastoid 8.7 (− 4.0, 21.8) 0.173 Not tested
Left sternocleidomastoid 7.9 (− 3.1, 19.0) 0.153 Not tested
Splenius capitis 5.2 (− 4.8, 15.2) 0.302 0.03 (0.004, 0.22)
Right psoas 4.6 (− 32.5, 42.4) 0.798 0.64 (0.45, 0.80)
Left forearm compartment 3.2 (− 27.1, 33.8) 0.828 Not tested
Left psoas 1.3 (− 46.1, 46.4) 0.995 0.64 (0.45, 0.80)
Right trapezius 0.6 (− 11.4, 11.5) 0.991 Not tested
Right forearm compartment -8.9 (− 36.2, 17.7) 0.502 Not tested
Left triceps − 20.0 (− 52.6, 10.5) 0.192 0.14 (0.03, 0.33)
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between patients [mean age 57 years (SD 14), 7 females, 
mean weight 78 kg (SD 15)] and controls [54 years (SD 16), 
9 females, 75 kg (SD 15), all p > 0.05]. In patients, mean 
ALSFRS-R and median MRC summary score were 40/48 
(SD 4.5) and 161/170 (SD 10.6), respectively. Fourteen 
patients presented with upper limb-onset, 11 patients lower 
limb-onset, and four patients bulbar-onset disease. Patients 
were assessed at a median of 66 weeks from symptom onset 
(median 90 and 57 weeks for 12 month completer and non-
completer subgroups, respectively). Median follow-up was 
at 19 and 55 weeks for patients and 29 weeks for controls.
Baseline diferences between MND patients 
and controls
Radiological and clinical differences are reported in 
Table 1. There were signiicant diferences in relative T2 
signal but no signiicant diferences in apparent difusion 
coeicient (ADC) between patients and controls. Electro-
physiological diferences are reported in Table 2.
Fig. 2  Participant follow-up. MND motor neuron disease, MRI magnetic resonance imaging, MUNIX motor unit number index
Table 2  Neurophysiological diferences between MND patients and controls, by muscle, at baseline, listed in order of maximal MUNIX difer-
ences
Signiicant diferences between MND patients and controls are highlighted in bold. Results surviving multiple comparisons correction are aster-
isked. The least afected muscle in each patient and the right side in controls were tested
CI conidence interval, CMAP compound muscle action potential, MUNIX motor unit number index, MUSIX motor unit number size
Muscle Percentage diferences between patients and controls (95% CI)
MUNIX p value MUSIX p value CMAP p value
Abductor pollicis brevis − 50 (− 67, − 34) < 0.001* 17 (− 4, 39) 0.115 − 37.7 (− 55.3, − 20.1) < 0.001*
Abductor hallucis − 50 (− 71, − 29) < 0.001* − 7 (− 33, 20) 0.611 − 41.5 (− 61.1, − 21.8) < 0.001*
Extensor digitorum brevis − 44 (− 69, − 19) 0.001* − 21 (− 51, 10) 0.180 − 41.8 (− 64.0, − 19.6) < 0.001*
Tibialis anterior − 39 (− 56, − 22) < 0.001* 43 (11, 76) 0.011* − 22.2 (− 40.2, − 4.3) 0.016*
Biceps brachii − 36 (− 52, − 20) < 0.001* 4 (− 8, 16) 0.522 − 30.2 (− 46.6, − 13.9) 0.001*
Abductor digiti minimi − 34 (− 51, − 16) < 0.001* 20 (− 1, 41) 0.057 − 29.4 (− 45.5, − 15.3) < 0.001*
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Clinical, electrophysiological and radiological 
associations
Associations between relative T2-weighted MR in 
each tested muscle with clinical power using hand-held 
dynamometry and MUNIX are reported in Table 3.
For ADC, the only inding was that greater weakness in 
left tibialis anterior was associated with higher ADC (regres-
sion coeicient − 0.032 (− 0.057, − 0.008), p = 0.012*).
Longitudinal changes
Longitudinal clinical, electrophysiological and relative 
T2-signal changes in MND patients are reported in Tables 4 
and 5.
Decreases in median MRC of up to one point were found 
in the following muscles at 4 months: left abductor pollicis 
brevis, right irst dorsal interosseous, left wrist extensors, 
bilateral hamstrings, and right tibialis anterior; and in the 
following muscles at 12 months: left abductor pollicis bre-
vis, bilateral irst dorsal interossei, and left abductor digit 
minimi. Right tibialis anterior MRC decreased by 1.5 points 
at 12 months (all p < 0.05). Median MRC summary score 
was 103/170 at baseline, 94/170 at 4 months (p < 0.05), and 
97/170 at 12 months (p < 0.05 from baseline).
ADC decreased only in patients’ right sternocleidomas-
toid at 12 months (regression coeicient − 366.1 (− 557.8, 
− 174.4), p < 0.001*).
There were no signiicant changes in healthy controls in 
any measure.
Individualized plots of longitudinal relative T2-weighted 
changes summarized for all muscles, by region-of-onset, by 
muscle-of-onset and for a single leg muscle (right tibialis 
anterior), are illustrated in Fig. 3.
Baseline predictors of subsequent muscle weakness
Associations between higher baseline relative T2 muscle 
signal and subsequent development of clinical weakness 
were found in right thenar eminence [regression coei-
cient (r) = − 3.88 (95% CI − 7.21, − 0.55), p = 0.025), right 
gluteus maximus (r = − 0.53 (− 0.93, − 0.12), p = 0.014), 
bilateral quadriceps (right: r = − 1.29 (− 2.53, − 0.04), 
p = 0.044; left: r = − 1.11 (− 2.00, − 0.21, p = 0.018) right 
hamstrings (r = − 1.63 (− 3.21, − 0.04), p = 0.045) and left 
gastrocnemius/soleus at four months (r = − 2.01 (− 2.93, 
− 1.08), p < 0.001*); and right hamstrings (r = − 2.24 
(− 4.15, − 0.33), p = 0.025), right tibialis anterior (r = − 7.41 
(− 12.47, − 2.35), p = 0.008) and left gastrocnemius/soleus at 
12 months (r = − 2.89 (− 4.24, − 1.54), p = 0.001*).
Table 3  Clinico-electrophysiological-radiological associations in MND patients
Signiicant associations between dynamometry scores, motor unit number index and relative T2-signal in corresponding muscles are reported in 
bold. Results surviving multiple comparisons correction are asterisked. Electrophysiological measures were derived from the least afected side 
in patients and regressed against clinical measures of corresponding laterality
CI conidence interval, lb, pounds force, MUNIX motor unit number index, SD standard deviation
Muscle Mean (SD) 
dynamometry
(lb)
Mean (SD) MUNIX Clinico-radiological 
association coeicient 
(95% CI)
p value Electro-physiological-
radiological association 
coeicient (95% CI)
p value
Right biceps Not tested 129.3 (53.9) Not tested Not tested 9.7 (− 128.9, 148.4) 0.885
Left biceps
Right irst dorsal inter-
osseous
4.8 (3.5) Not tested − 10.9 (− 17.0, − 4.8) 0.001* Not tested Not tested
Left irst dorsal interos-
seous
4.7 (3.4) − 6.6 (− 11.8, − 1.5) 0.014*
Right abductor pollicis 
brevis
6.4 (4.6) 82.8 (52.2) − 13.7 (− 24.5, − 2.9) 0.015* − 74.2 (− 207.1, 58.7) 0.258
Left abductor pollicis 
brevis
7.0 (5.1) 6.0 (− 3.4, 15.4) 0.199
Right abductor digiti 
minimi
3.4 (2.1) 123.2 (68.0) − 8.0 (− 16.4, 0.4) 0.061 − 86.9 (− 380.9, 207.1) 0.543
Left abductor digiti 
minimi
2.9 (1.9) − 6.4 (− 12.2, − 0.6) 0.034
Right quadriceps 42.8 (11.5) Not tested − 56.6 (− 84.8, − 28.4) < 0.001* Not tested Not tested
Left quadriceps 43.6 (12.6) − 51.2 (− 82.0, − 20.4) 0.002*
Right tibialis anterior 34.0 (19.8) 83.5 (48.6) − 93.0 (− 122.2, − 63.8) < 0.001* − 232.0 (− 343.1, 
− 120.9)
< 0.001*
Left tibialis anterior 36.5 (21.8) − 108.1 (− 133.6, − 82.6) < 0.001*
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When only clinically normal muscles at baseline were 
included, higher baseline relative T2-signal was associ-
ated with development of weakness in right gluteal mus-
cles (r = − 0.72 (95% CI − 1.15, − 0.29), p = 0.002*), 
right hamstrings (r = − 2.00 (95% CI − 3.03, − 0.97), 
p = 0.001*) and left gastrocnemius (r = − 1.19 (95% CI 
− 2.00, − 0.38), p = 0.007*) at 4, but not 12 months.
Discussion
This study represents the most comprehensive longitudinal 
analysis of muscle-based clinical, electrophysiological and 
imaging biomarkers in MND to date, combining multi-
modal assessments across multiple muscles. The key result 
Table 4  Longitudinal clinical and electrophysiological changes in MND patients
Signiicant changes in clinical and electrophysiological parameters in MND patients between baseline and subsequent four and 12 month time-
points are highlighted in bold. Results surviving multiple comparisons correction are asterisked. Electrophysiological measures were derived 
from the least afected side in each patient at baseline and the same muscle was retested at each follow-up
ALSFRS-R amyotrophic lateral sclerosis functional rating scale- revised, CI conidence interval, CMAP compound muscle action potential, lb 
pounds force, MUNIX motor unit number index, MUSIX motor unit number size, SRM standardized response mean, Var variance
Muscle Mean diference between base-
line and four months (95%CI)
p value Mean diference between 
baseline and 12 months 
(95%CI)
p value SRM Var ratio
Clinical scores
 ALSFRS-R − 3.4 (− 4.9, − 1.8) < 0.001* − 5.7 (− 7.6, − 3.8) < 0.001* − 1.22 0.78
Dynamometry (lb)
 Right irst dorsal interosseous − 1.1−  (− 1.9, − 0.4) 0.005* − 1.9 (− 2.8, − 0.9) < 0.001* − 0.74 0.86
 Left irst dorsal interosseous − 1.0 (− 1.7, − 0.3) 0.004* − 2.0 (− 2.8, − 1.1) < 0.001* − 0.85 0.89
 Right abductor pollicis brevis − 0.2 (− 1.5, 1.2) 0.804 − 1.5 (− 3.2, 0.2) 0.081 − 0.38 0.79
 Left abductor pollicis brevis − 1.1 (− 2.9, 0.7) 0.250 − 2.1 (− 4.3, 0.2) 0.068 − 0.43 0.69
 Right abductor digiti minimi − 0.6 (− 1.3, 0.1) 0.070 − 1.0 (− 1.8, − 0.2) 0.015* − 0.36 0.70
 Left abductor digiti minimi − 0.8 (− 1.3, − 0.2) 0.005* − 1.4 (− 2.0, − 0.7) < 0.001* − 0.89 0.79
 Right quadriceps − 3.1 (− 7.4, 1.1) 0.149 − 4.6 (− 9.8, 0.6) 0.085 − 0.46 0.63
 Left quadriceps − 2.8 (− 7.6, 2.0) 0.250 − 3.6 (− 9.5, 2.3) 0.234 − 0.36 0.57
 Right tibialis anterior − 4.9 (− 10.0, 0.3) 0.064 − 10.7 (− 17.0, − 4.4) 0.001* − 0.73 0.85
 Left tibialis anterior − 8.4 (− 14.6, − 2.2) 0.008* − 9.3 (− 16.9, − 1.7) 0.016* − 0.64 0.79
MUNIX
 Biceps brachii − 19 (− 33, − 4) 0.013* − 23 (− 42, − 4) 0.017* − 0.45 0.85
 Abductor pollicis brevis − 23 (− 33, − 12) < 0.001* − 33 (− 46, − 20) < 0.001* − 1.47 0.90
 Abductor digiti minimi − 45 (− 62, − 21) < 0.001* − 66 (− 92, − 41) < 0.001* − 1.08 0.72
 Tibialis anterior − 11 (− 17, − 5) < 0.001* − 20 (− 27, − 13) < 0.001* − 1.59 0.96
 Abductor hallucis − 1 (− 23, 6) 0.234 − 28 (− 45, − 11) 0.001* − 0.72 0.93
 Extensor digitorum brevis − 2 (− 12, 8) 0.645 − 10 (− 23, 2) 0.108 − 0.40 0.83
MUSIX
 Biceps brachii 2 (− 1, 6) 0.212 1 (− 3, 6) 0.710 0.17 0.67
 Abductor pollicis brevis 5 (− 22, 33) 0.701 20 (− 14, 53) 0.253 0.23 0.21
 Abductor digiti minimi 6 (− 9, 21) 0.448 33 (15, 51) < 0.001* 1.04 0.27
 Tibialis anterior 5 (− 12, 22) 0.537 − 3 (− 23, 17) 0.778 − 0.12 0.68
 Abductor hallucis 3 (− 3, 9) 0.317 8 (1, 15) 0.031* 0.92 0.92
 Extensor digitorum brevis 1 (− 14, 16) 0.852 5 (− 14, 23) 0.621 0.05 0.83
CMAP
 Biceps brachii − 0.7 (− 1.2, − 0.2) 0.004* − 1.2 (− 1.8 to − 0.5) 0.001* − 0.86 0.88
 Abductor pollicis brevis − 1.1 (− 1.6, − 0.6) < 0.001* − 2.1 (− 2.8 to − 1.5) < 0.001* − 1.36 0.93
 Abductor digiti minimi − 1.2 (− 2.0, − 0.4) 0.002* − 2.2 (− 3.1 to − 1.2) < 0.001* − 0.87 0.86
 Tibialis anterior − 0.3 (− 0.7, 0.1) 0.191 − 1.0 (− 1.5, − 0.5) < 0.001* − 0.85 0.89
 Abductor hallucis − 0.6 (− 1.2, 0.1) 0.099 − 1.2 (− 2.0, − 0.4) 0.003* − 0.66 0.95
 Extensor digitorum brevis − 0.1 (− 0.6, 0.3) 0.553 − 0.7 (− 1.3, − 0.1) 0.017* − 0.86 0.92
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is that no single technique or muscle fully captured change 
at group level; diferent assessment tools were diferen-
tially sensitive in diferent muscles. We hypothesized that 
whole-body muscle imaging would capture widespread 
progression of denervation, but instead found that leg 
muscle changes were the most efective radiological bio-
marker in this cohort, regardless of clinical onset-site and, 
importantly, detected changes in slow progressors, an area 
of need for clinical trials.
Table 5  Longitudinal radiological changes in relative T2-signal in MND patients
Signiicant T2-weighted radiological changes in MND patients between baseline and subsequent four and 12 month time-points are highlighted 
in bold. Results surviving multiple comparisons correction are asterisked
CI conidence interval, SRM standardized response mean, Var variance
Muscle Regression coeicientMean % 
change in relative T2-signal 
between baseline and four months 
(95%CI)
p value Regression coeicientMean % 
change in relative T2-signal 
between baseline and 12 months 
(95%CI)
p value SRM Var ratio
Tongue − 0.04 (− 0.09, 0.01) − 4.8 (− 11.2, 
1.5)
0.123 − 2.4–0.02 (− 10.20.08, 5.4 0.04) 0.540 − 0.08 0.66
Right trapezius − 6.90.03 (− 19.10.09, 5.20.02) 0.251 0.20.001 (− 14.50.07, 14.80.07) 0.981 0.06 0.17
Left trapezius − 10.90.06 (− 22.90.1, 0.0904) 0.066 − 1.7–0.009 (− 16.10.08, 12.80.06) 0.816 − 0.02 0.17
Right sternocleidomastoid − 3.70.02 (− 13.40.06, 6.00.03) 0.443 0.3002 (− 11.50.05, 12.20.05) 0.949 0.10 0.43
Left sternocleidomastoid − 4.40.03 (− 14.50.08, 5.60.03) 0.376 − 4.1 0.02 (− 16.30.09, 8.20.04) 0.502 − 0.11 0.37
Splenius capitis 4.20.03 (− 4.30.03, 12.80.08) 0.321 − 5.40.03 (− 16.00.1, 5.10.03) 0.297 − 0.42 0.47
Right deltoid 2.70.009 (− 5.00.02, 10.40.04) 0.486 − 4.80.02 (− 14.40.05, 4.70.02) 0.304 − 0.27 0.71
Left deltoid 1.90.008 (− 6.60.03, 10.40.04) 0.654 4.60.02 (− 5.80.02, 15.20.06) 0.365 0.08 0.59
Right biceps brachii − 2.20.01 (− 13.80.06, 9.40.04) 0.700 11.3 0.05 (− 2.9–0.01, 25.70.1) 0.107 0.18 0.55
Left biceps brachii − 3.5–0.009 (− 17.40.05, 0.10.103) 0.597 − 1.90.005 (− 18.60.05, 14.70.04) 0.814 − 0.21 0.26
Right triceps − 13.90.06 (− 47.20.2, 18.00.07) 0.378 − 22.30.09 (− 65.10.2, 18.40.07) 0.266 − 0.19 0.10
Left triceps − 0.00 (− 31.3–0.08, 31.2 0.08) 0.998 –0.00.02 (− 22.10.1, 22.10.09) 0.708 − 0.18 0.00
Right brachioradialis 7.30.02 (− 15.00.05, 29.0.09) 0.507 10.40.03 (− 15.40.05, 36.80.1) 0.414 0.04 0.06
Left brachioradialis 7.00.02 (− 16.80.05, 31.20.09) 0.551 9.90.03 (− 19.30.06, 39.60.1) 0.492 0.82 0.23
Right irst dorsal interosseous 18.4 0.1 (− 1.8–0.007, 39.80.2) 0.067 31.10.2 (6.80.04, 57.40.3) 0.010 0.64 0.43
 Left irst dorsal interosseous − 0.002 (− 26.20.07, 24.60.07) 0.952 16.10.05 (− 16.20.05, 50.40.1) 0.311 0.97 0.41
 Right thenar 14.40.07 (− 7.10.03, 36.60.17) 0.177 21.40.1 (− 4.90.02, 48.90.2) 0.100 0.76 0.26
 Left thenar − 8.70.02 (− 42.10.1, 23.80.06) 0.586 − 10.0–0.03 (− 50.10.1, 29.8 0.08) 0.607 − 0.57 0.17
 Right hypothenar 5.50.02 (− 10.60.03, 22.00.06) 0.491 13.80.04 (− 5.8, 0.02,34.4 0.1) 0.155 0.27 0.73
 Left hypothenar 3.10.01 (− 12.60.05, 18.80.08) 0.691 2.30.009 (− 16.20.06, 20.90.08) 0.802 0.22 0.34
 Right thoracic paraspinal − 1.00.005 (− 4.40.09, 2.40.08) 0.903 16.70.09 (− 3.00.01, 37.60.2) 0.087 0.30 0.69
 Left thoracic paraspinal 1.60.01 (− 12.10.08, 15.50.1) 0.811 4.20.03 (− 12.70.08, 21.40.14) 0.610 0.24 0.70
Right psoas 6.20.03 (− 19.90.08, 33.10.1) 0.627 35.70.2 (4.60.02, 71.10.3) 0.020 0.53 0.52
 Left psoas − 11.80.04 (− 42.80.1, 17.90.06) 0.419 − 15.70.06 (− 54.10.2, 20.90.07) 0.382 − 0.01 0.31
 Right gluteus maximus − 3.00.02 (− 24.30.1, 18.10.1) 0.774 22.00.1 (− 3.1–0.02, 48.80.3) 0.076 0.44 0.49
 Left gluteus maximus − 14.2 0.1 (− 42.30.3, 12.20.09) 0.277 –14.80.1 (− 49.8–0.4, 18.40.1) 0.363 − 0.10 0.53
Right quadriceps 5.40.02 (− 2.5− ,0.008, 13.60.05) 0.168 018.8.07 (9.00.03, 29.60.1)  < 0.001* 0.86 0.90
Left quadriceps 1.20.004 (− 7.40.02, 9.70.03) 0.784 11.40.04 (2.90.004, 20.60.07) 0.028 0.39 0.91
Right hamstrings − 2.20.007 (− 10.20.03, 5.60.02) 0.564 17.40.05 (7.70.02, 28.20.08)  < 0.001* 0.98 0.93
Left hamstrings 1.90.008 (− 7.10.03, 11.00.05) 0.666 14.40.06 (3.30.02, 26.30.1) 0.008* 0.65 0.89
Right tibialis anterior 10.70.04 (0.8004, 21.20.07) 0.030 28.50.1 (15.90.06, 42.70.1)  < 0.001* 0.82 0.87
Left tibialis anterior 4.10.02 (− 7.90.01, 16.50.06) 0.180 20.90.07 (6.00.02, 37.20.11) 0.004* 0.33 0.86
Right gastrocnemius/soleus 5.60.02 (− 3.20.01, 14.70.06) 0.200 18.90.07 (8.00.03, 30.60.1)  < 0.001* 0.64 0.83
Left gastrocnemius/soleus 0.5003 (− 8.20.04, 9.10.05) 0.911 18.70.1 (8.0(0.05, 30.30.2)  < 0.001* 0.78 0.88
 Muscle-of-onset − 0.102 (− 16.10.10, 16.0 0.07) 0.698 16.60.10 (− 2.90.008, 37.3) 0.20) 0.070 0.77 0.73
Region-of-onset 2.70.01 (− 4.30.02, 9.70.04) 0.437 14.10.06 (5.50.03, 23.2 0.10) 0.001* 0.87 0.89
Summary mean − 0.1.0004 (− 6.20.03, 5.90.03) 0.972 8.80.04 (1.30.007, 16.4 0.07) 0.017 0.36 0.56
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At baseline, clinical weakness was frequent in left abduc-
tor digiti minimi (ADM), bilateral irst dorsal interosseous 
and bilateral psoas. Of these muscles, ADM weakness is 
perhaps surprising, because generally considered relatively 
spared in MND, at least in terms of wasting (the basis of the 
split hand phenomenon), whilst involvement of irst dorsal 
interosseous is typical [29]. Patients exhibited greater motor 
unit loss in abductor pollicis brevis than ADM at baseline, 
but MUNIX also dropped signiicantly in ADM over time, 
and this muscle appeared commonly afected in this cohort. 
In general, radiological changes were associated with clini-
cal weakness more frequently than with electrophysiologi-
cal motor unit loss, although associations with both were 
evident in tibialis anterior. Radiological increases in relative 
T2-signal likely relect muscle luid changes, and later fatty 
replacement [30], and appear a consistent inding in MND. 
Qualitative T2 changes have been reported in the tongue 
[12] and arm muscles [9, 10], and quantitative changes in 
a small cohort in leg muscles [13]. In a very recently pub-
lished paper, diferences between MND patients and healthy 
controls were demonstrated in leg muscles on T2-weighted 
short tau inversion recovery imaging evaluated with rater 
scales, but there were no diferences in quantitative fat frac-
tion imaging in either the leg muscles or tongue [31]. In 
contrast to T2 signal, muscle volume changes appear modest 
[14, 16, 17]. Our data suggest that muscle relative T2-signal 
change may capture aspects of pathophysiology contributing 
to weakness other than loss of electrophysiological motor 
units. Associations between high baseline relative T2-signal 
and development of weakness in some muscles, even when 
clinically strong, suggests this may occur early, an intriguing 
inding that merits further investigation.
The diiculties of capturing change in MND with simple 
clinical measures, such as MRC scores, were illustrated in 
this study and highlight the challenges of phenotypical heter-
ogeneity. Group-level longitudinal changes were detectable 
in irst dorsal interosseous and tibialis anterior on dynamom-
etry, muscles generally recognized as typically afected in 
MND [29, 32], but this test is efort-dependent [4]; despite 
its known limitations, ALSFRS-R proved the most respon-
sive longitudinal clinical measure in this study. This is likely 
to relect the generally lower variance of ALSFRS-R com-
pared to muscle T2 values outside the leg muscles, as illus-
trated in Tables 4 and 5, and the mortality-related attrition 
common to MND studies may also have biased the 12-month 
SRM estimate for ALSFRS-R. Muscle MR has some advan-
tages over ALSFRS-R not captured by SRM estimates, 
namely objectivity, independence from potential confounds 
Fig. 3  Longitudinal changes in MND patients in relative T2-weighted 
MR signal: whole-body summary mean (a); region-of-onset (b); sin-
gle muscle-of-onset (c) and right tibialis anterior (d). Red lines indi-
cate patients with lower limb-onset, blue lines upper limb-onset and 
green lines bulbar-onset. The bold black dashed line indicates all 
patients mean. The magenta dashed lines indicate the healthy control 
mean where relevant
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of therapeutic intervention, and assessment of pathophysi-
ological efects rather than their symptomatic consequences. 
These assessment methods appear complementary. It is pos-
sible that a fully quantitative T2 relaxometry protocol could 
reduce the error variance and increase the responsiveness of 
the MR measurements, but this question cannot be answered 
by the present study.
On objective tests, progressive electrophysiological motor 
unit loss was evident, as in previous studies [33], especially 
in tibialis anterior and abductor pollicis brevis. Interestingly, 
there was only limited evidence of reinnervation on MUSIX, 
at baseline or longitudinally. We examined the strongest side 
in patients, which may indicate that MUSIX changes lag 
behind MUNIX, because subclinical or early motor unit loss 
had not yet triggered reinnervation. We also pooled weak 
and strong muscles which may have diluted overall difer-
ences in a relatively small cohort. Limitations of MUNIX/
MUSIX are that patient efort is required, not all muscles 
are amenable to study, only relatively few can be assessed 
in a session, and “loor efects” exist. Our data suggest that 
tibialis anterior and abductor pollicis brevis represent good 
targets. Floor efects also exist for clinical measures, such 
as dynamometry and MRC scores. We did not adjust for this 
efect in our analysis (for example, by excluding patients 
with low MRC scores at baseline from further analysis). This 
could be explored in a larger, adequately powered cohort.
This was the irst application of whole-body difusion-
weighted MR to assess muscle tissue integrity in MND. 
Very few changes were found, either because opposing 
efects of pathophysiological processes occurred or due to 
technical factors. It is possible that concurrent efects of 
myoibrillar cell membrane damage and increased intra-
muscular luid increased difusion, whilst consequent cel-
lular debris and increased fat deposition caused a decrease, 
resulting in no detectable net ADC change. Alternatively, 
exponential signal intensity decay at high b values may have 
resulted in loss of signal. A previous study of muscle den-
ervation in rats applied a lower b value of 600 s/mm2 [34], 
compared to b = 1000 s/mm2 used in this study. We conclude 
that T2-weighted muscle imaging approaches appear more 
sensitive to MND change than difusion-weighted MR, at 
least using the parameters applied.
Leg muscles appear the best target for future fully quan-
titative T2 studies, although assessment in an independent 
cohort is necessary to determine whether this inding is gen-
eralizable. Whilst an increase in whole-body relative T2 was 
evident, this did not survive adjustment for multiple com-
parisons. Longitudinal changes were more readily detectable 
in the lumbar region, compared with cranial, cervical and 
thoracic body segments. This does not appear to be attribut-
able to clinical factors; whilst lower limb-onset and progres-
sion were quite prevalent in our cohort, this was also the case 
for arm muscles. Technical factors may have contributed; leg 
muscles are larger, central within the acquisition ield-of-
view, with clearly deined anatomical boundaries, and these 
factors could inluence the observed lower regression vari-
ance ratios. Measurement error might be reduced by devel-
oping fully automated analysis algorithms for whole-body 
MR in the future. Technical factors also prevented assess-
ment of other muscles of interest, such as the diaphragm, 
which was not consistently identiiable using the slice thick-
ness applied in this study. Thinner slices are possible but 
would necessitate longer scan-times.
Despite cohort attrition, typical of longitudinal cohort 
studies in MND, resulting in lower statistical power, longi-
tudinal relative T2 changes from baseline were more marked 
at 12 than 4 months. In our previous study, which assessed 
this cohort to four months using diferent methodology, lon-
gitudinal changes were identiied in tibialis anterior (and not 
in biceps brachii, thoracic paraspinals or the tongue) [17]. 
In the present analysis, similar results were found, despite 
a diferent methodology (assessing axial rather than coro-
nal slices) performed by a diferent operator. Progressive 
denervation efects were again only found in leg muscles, 
including right tibialis anterior at both 4 and 12 months. 
Although the previously identiied increase in relative T2 
signal in left tibialis anterior did not reach statistical signii-
cance at 4 months in the present analysis (probably due to 
sampling diferences), changes in this muscle were detect-
able at 12 months. Changes in dynamometry and electro-
physiology were again evident in leg muscles. It is inter-
esting to consider whether an MR “loor efect” exists, as 
for dynamometry and electrophysiology, when no further 
change is detectable because of complete paresis with absent 
motor potentials. This would require subgroup assessment 
in an adequately powered cohort.
A limitation of relative T2-weighted MR is the neces-
sity to adjust measurements to reference tissue within each 
acquisition station to allow for differential coil-loading 
efects between participants, because the sequence is not 
fully quantitative. This could have biased between-muscle 
comparisons. We sought to minimize bias by reporting per-
centage T2-signal diferences relative to healthy controls. 
Previous studies using similar sequences have applied quali-
tative grading scales and expert raters [9, 10]. We argue that 
our approach reduces subjectivity and has the advantage of 
producing continuous data, but measurement variance will 
be higher than fully quantitative T2 techniques. Despite 
these potential limitations, a clear pattern of biologically 
and clinically feasible results was evident. These considera-
tions illustrate the necessary trade-of between the number of 
muscles that can be studied concurrently and a feasible scan-
time for disabled MND patients. For similar reasons, we 
could not collect corresponding clinico-electrophysiological 
data for all muscles investigated with MR, or combine our 
assessments with other promising muscle techniques, such 
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as electrical impedance myography [35]. Nevertheless, our 
dataset still represents the most wide-ranging imaging and 
electrophysiological muscle assessment in MND to date. 
Our cohort demonstrated the heterogeneity in disease pro-
gression rates typical of the ALS population. It would be 
interesting to assess the utility of muscle biomarkers in a 
cohort of ALS patients selected for slow progression (> 0.9 
ALSFRS-R points/month), where these measures would add 
most value, in a future study.
In summary, this longitudinal study is the irst to dem-
onstrate clinically and electrophysiologically relevant pro-
gressive muscle denervation on MR across a wide range of 
muscle groups over 12 months. Although we hypothesized 
that whole-body muscle MR would capture generalized 
changes, our data suggest that leg muscles are sensitive 
to detect group-level longitudinal changes, irrespective of 
clinical onset-site, and could represent a biomarker target 
for future quantitative studies. Relative T2-weighted MR 
appeared more sensitive to detect denervation than difusion-
weighted MR.
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